Zhendong Pharmacy: Vaginal Lactobacillus Dual Live Bacteria Capsules Achieve Primary Research Endpoint

Zhendong Pharmacy announced that its investee company Longchuang Pharmaceutical's research project on vaginal Lactobacillus dual live bacteria capsules has reached the primary endpoint in the Phase III clinical trial. This capsule is used for the treatment of bacterial vaginosis caused by dysbiosis, employing an innovative mechanism of "treating bacteria with bacteria," which has differentiated advantages. The company will recently submit a communication application prior to the marketing authorization application to the National Medical Products Administration's Drug Evaluation Center, actively promoting the marketing process of this capsule